<DOC>
	<DOCNO>NCT01255592</DOCNO>
	<brief_summary>The purpose study investigate effect AZD5069 patient bronchiectasis .</brief_summary>
	<brief_title>Evaluation Effect AZD5069 Patients With Bronchiectasis</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Bronchiectasis</mesh_term>
	<mesh_term>Respiration Disorders</mesh_term>
	<mesh_term>Respiratory Tract Diseases</mesh_term>
	<criteria>Male , female nonchild bear potential ; ie , woman permanently surgically sterilise postmenopausal . Aged 18 80 year inclusive screening ( Visit 1 ) Have clinical diagnosis idiopathic post infective bronchiectasis diagnose historical high resolution computerise tomography ( HRCT ) bronchogram Be sputum producer history chronic expectoration day week year . Patients history spontaneously produce sputum daily basis able provide least 2 3 require baseline sputum sample average 3 mL . Be stable treatment regimen , judge investigator . Any clinically significant disease disorder Patients latent chronic infection risk infection within 90 day Visit 2 An acute exacerbation acute respiratory infection ( upper low ) require oral steroid antibiotic within 30 day prior Visit 2 An FEV1 &lt; 30 % predict normal Visit 1 Patients receive live liveattenuated vaccine 2 week prior dose ( Visit 2 ) Concomitant diagnosis significant pulmonary disease bronchiectasis COPD , include symptomatic asthma allergic bronchopulmonary aspergillosis Bronchiectasis associate generalised immunodeficiency disorder , manifestation bronchiectasis predominate</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>Bronchiectasis</keyword>
	<keyword>Neutrophil</keyword>
	<keyword>Respiratory disease</keyword>
	<keyword>Sputum</keyword>
</DOC>